INMAGENE BIOPHARMACEUTICALS
It is a leading biotech company focused on immunology-related therapeutic areas.
INMAGENE BIOPHARMACEUTICALS
Social Links:
Industry:
Biopharma Biotechnology Health Care
Address:
Pudong, Shandong, China
Country:
China
Website Url:
http://www.inmagenebio.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
121 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Office 365 Mail Microsoft Azure DNS HiChina DNS
Similar Organizations
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Employees Featured
Founder
Investors List
Kunlun Fund
Kunlun Fund investment in Series C - Inmagene Biopharmaceuticals
HT Capital
HT Capital investment in Series C - Inmagene Biopharmaceuticals
Panacea Venture
Panacea Venture investment in Series C - Inmagene Biopharmaceuticals
TriWise Capital
TriWise Capital investment in Series C - Inmagene Biopharmaceuticals
VMS Asset Management
VMS Asset Management investment in Series C - Inmagene Biopharmaceuticals
South China Venture Capital
South China Venture Capital investment in Series C - Inmagene Biopharmaceuticals
Highlight Capital
Highlight Capital investment in Series C - Inmagene Biopharmaceuticals
Kunlun Capital
Kunlun Capital investment in Series B - Inmagene Biopharmaceuticals
South China Venture Capital
South China Venture Capital investment in Series B - Inmagene Biopharmaceuticals
Vertex Ventures China
Vertex Ventures China investment in Series B - Inmagene Biopharmaceuticals
Official Site Inspections
http://www.inmagenebio.com Semrush global rank: 5.85 M Semrush visits lastest month: 1.42 K
- Host name: inmagene.tempurl.host
- IP address: 104.156.230.209
- Location: San Jose United States
- Latitude: 37.3387
- Longitude: -121.8914
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 95113
More informations about "Inmagene Biopharmaceuticals" on Search Engine
Ushering in a new era of therapies for immunological diseases ...
Advancement through excellence. We are working to usher in a new era of therapeutics to meaningfully improve outcomes for patients with immunologic and inflammatory …See details»
Inmagene Biopharmaceuticals - Crunchbase Company …
Inmagene is a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases.See details»
Inmagene Biopharmaceuticals | LinkedIn
Inmagene is a global clinical-stage biotechnology company developing novel therapeutics for I&I diseases. The company’s highly differentiated clinical-stage pipeline …See details»
Inmagene Doses First Patient in Phase 2a Trial of IMG …
Oct 13, 2023 Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunological and inflammatory diseases. It has four …See details»
Inmagene and HUTCHMED Announce First Participants …
Jul 6, 2022 Inmagene is working with its partners to conduct global phase II studies for multiple autoimmune diseases, including PsA, ankylosing spondylitis (AS) and uveitis.See details»
Inmagene and HUTCHMED Announce First Participant in Global …
Aug 9, 2022 Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunology-related diseases. The company is building …See details»
Inmagene and HUTCHMED Announce First Participant …
Aug 9, 2022 Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunology-related diseases. The company is building …See details»
Chi-Med and Inmagene Announce Strategic Partnership to …
Jan 11, 2021 Inmagene, with wholly owned subsidiaries in Shanghai, San Diego, and Hangzhou, is one of the leading companies in immunology drug development in China. It …See details»
Inmagene Biopharmaceuticals - Funding, Financials, …
Inmagene is a clinical-stage biotech company developing innovative and differentiated therapies for immunological and inflammatory diseases.See details»
Chi-Med and Inmagene Announce Strategic Partnership to
Jan 11, 2021 Inmagene, with wholly owned subsidiaries in Shanghai, San Diego, and Hangzhou, is one of the leading companies in immunology drug development in China. It …See details»
Inmagene Exercises Option to Obtain Exclusive Worldwide …
Feb 2, 2024 Inmagene is a global clinical-stage biotechnology company developing novel therapeutics for I&I diseases. The company's highly differentiated clinical-stage …See details»
Inmagene Biopharmaceuticals - 2021-06-01 - Crunchbase
News • Jun 1, 2021. 24HTECH.ASIA — China’s HLC, Panacea lead $100m funding in biotech startup Inmagene. Unlock even more features with Crunchbase Pro. Start Your …See details»
Affibody and Inmagene Announce Strategic ... - Affibody Medical AB
May 15, 2020 Affibody AB (“Affibody”) and Inmagene Biopharmaceuticals (“Inmagene”) today announced a strategic partnership to develop and commercialize ABY-035, a …See details»
HUTCHMED
Jan 11, 2021 About Inmagene Biopharmaceuticals. Inmagene, with wholly owned subsidiaries in Shanghai, San Diego, and Hangzhou, is one of the leading companies in …See details»
Inmagene and HUTCHMED Announce First Participants in …
Jul 6, 2022 IMG-007 is a novel antagonistic monoclonal antibody targeting the OX40 receptor. It was originally discovered by HUTCHMED, with Inmagene assuming …See details»
Immagene, Aditum Bio Partner to Create New Biotech Company
Sep 21, 2023 Immagene Biopharmaceuticals and Aditum Bio have announced a joint venture to create Celexor Bio, a new biotech company focused on cell depletion of …See details»
Inmagene Receives FDA's IND Clearance for OX40 Antagonist
Apr 30, 2022 Inmagene is a global clinical-stage biotechnology company focused on developing novel therapeutics for immunology-related diseases. The company is building …See details»
Inmagene Biopharmaceuticals | VentureRadar
"Inmagene, with wholly owned subsidiaries in San Diego, Shanghai, Hangzhou, Sydney and Wuhan, is a global clinical-stage biotech company focused on developing novel …See details»
Inmagene Biopharmaceuticals - 2020-11-08 - Crunchbase
News • Nov 8, 2020. Unlock even more features with Crunchbase Pro. Start Your Free Trial. Inmagene Biopharmaceuticals raised $21000000 on 2020-11-08 in Series B.See details»
Inmagene Biopharmaceuticals | CipherBio
Explore Inmagene Biopharmaceuticals's investment information, scientific platforms, therapeutic approaches, indications and more here!See details»